Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 160

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 160
---
 Oncotelic totaling $70,000. The loan payable from Oncotelic
totaling $70,000 was paid in full along with accrued interest on December 12, 2024. (see Note 13 to the accompanying consolidated financial
statements).

Recent Accounting
Pronouncements

For a detailed description of recent accounting pronouncements,
see Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements included in Part IV, Item 15 of
this Report and begin on page F-1 with the index to consolidated financial statements.

    ITEM 7A.
    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company” as defined
in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this item.

    ITEM 8.
    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The financial statements and supplementary data required
by this item are included in Part IV, Item 15 of this Report and begin on page F-1 with the index to consolidated financial statements.

    ITEM 9.
    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Resignation of Auditors

On May 21, 2024, KMJ Corbin & Company LLP (“KMJ”)
resigned as the Company’s independent registered public accounting firm because KMJ’s partners and professional staff joined
Crowe LLP. The Company’s Audit Committee approved the resignation on the same day.

During the Company’s years ended December 31,
2023 and 2022 and the subsequent interim period through the date of resignation, there were no disagreements between the Company and KMJ
on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements,
if not resolved to the satisfaction of KMJ, would have caused KMJ to make reference to the subject matter of the disagreements in connection
with its audit reports on the Company’s consolidated financial statements.

The Company engaged Rose, Snyder & Jacobs LLP
as its new independent registered public accounting firm on May 22, 2024.

 36 

    ITEM 9A.
    CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our President
and Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial and accounting officer,
respectively), evaluated